Stephanie A. Schultz,Zahra Shirzadi,Aaron P. Schultz,Lei Liu,Colleen D. Fitzpatrick,Eric McDade,Nicolas R. Barthelemy,Alan Renton,Bianca Esposito,Nelly Joseph‐Mathurin,Carlos Cruchaga,Charles D. Chen,Alison Goate,Ricardo Francisco Allegri,Tammie L. S. Benzinger,Sarah Berman,Helena C. Chui,Anne M. Fagan,Martin R. Farlow,Nick C. Fox,Brian A. Gordon,Gregory S. Day,Neill R. Graff‐Radford,Jason J. Hassenstab,Bernard J. Hanseeuw,Anna Hofmann,Clifford R. Jack,Mathias Jucker,Celeste M. Karch,Robert A. Koeppe,Jae‐Hong Lee,Allan I. Levey,Johannes Levin,Ralph N. Martins,Hiroshi Mori,John C. Morris,James Noble,Richard J. Perrin,Pedro Rosa‐Neto,Stephen P. Salloway,Raquel Sanchez‐Valle,Peter R. Schofield,Chengjie Xiong,Keith A. Johnson,Randall J. Bateman,Reisa A. Sperling,Jasmeer P. Chhatwal,the Dominantly Inherited Alzheimer Network Investigators

Abstract:Although pathogenic variants in PSEN1 leading to autosomal‐dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. PSEN1 variant carriers participating in the Dominantly Inherited Alzheimer Network were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. While both CY and TM groups were found to have similarly elevated beta‐amyloid burden compared to non‐carriers, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels compared to CY carriers. Although pathogenic variants in PSEN1 leading to autosomal‐dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non‐carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated Aβ compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre‐symptomatic and symptomatic phases of disease as compared to CY, using both cross‐sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by γ‐secretase and the generation of toxic β‐amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.

Alzheimer's disease induced neurons bearing PSEN1 mutations exhibit reduced excitability

Alzheimer’s disease induced neurons bearing mutations exhibit reduced excitability

Familial Alzheimer's Disease Neurons Bearing Mutations in PSEN1 Display Increased Calcium Responses to AMPA as an Early Calcium Dysregulation Phenotype

A heterozygous de novo PSEN1 mutation in a patient with early-onset parkinsonism

Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p.Ile416Thr variant mirror Alzheimer's disease neuropathology

Early pathogenic event of Alzheimer's disease documented in iPSCs from patients with PSEN1 mutations.

Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer's disease through disrupted regulated intramembrane proteolysis

PSEN1 E280A Cholinergic-like Neurons and Cerebral Spheroids Derived from Mesenchymal Stromal Cells and from Induced Pluripotent Stem Cells Are Neuropathologically Equivalent

PSEN1 Mutant Ipsc-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease

iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype

Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis.

A Three-Dimensional Alzheimer’s Disease Cell Culture Model Using iPSC-Derived Neurons Carrying A246E Mutation in PSEN1

The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestations

Cortical Neurodegeneration Caused by Psen1 Mutations is Independent of Aβ.

A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimer's Disease Increases Aβ42/Aβ40 Ratio.

A Novel PSEN1 K311R Mutation Discovered in Chinese Families with Late-Onset Alzheimer's Disease Affects Amyloid-β Production and Tau Phosphorylation.

Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease

Patient with PSEN1 Glu318Gly and Other Possible Disease Risk Mutations, Diagnosed with Early Onset Alzheimer's Disease

Presenilin-1 ΔE9 mutation associated sarcoplasmic reticulum leak alters [Ca2+]i distribution in human iPSC-derived cardiomyocytes

Pathophysiologic abnormalities in transgenic mice carrying the Alzheimer disease PSEN1 Δ440 mutation

Presenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial Alzheimer’s Disease